SAN DIEGO, April 16, 2018 /PRNewswire/ -- Viriom Inc. today announced that its study report "Elsulfavirine/VM1500A Long-Acting Parenteral and Oral Formulations for Treatment and Prevention of HIV-1 Infections" will be presented by Dr. Vadim Bichko, Viriom's Chief Scientific Officer, at the International Conference on HIV/AIDS, STDs & STIs on April 24th, 2018 in Valencia, Spain. The study evaluates new options for treatment and prevention of HIV/AIDS that would allow for infrequent dosing, thus facilitating patients' compliance and likely improving long-term treatment outcomes.
VM1500A is a new potent non-nucleoside HIV-1 reverse transcriptase inhibitor. Its orally-bioavailable prodrug, Elsulfavirine/Elpida®, is marketed in Eastern Europe as 20 mg oral QD regimen for HIV/AIDS treatment. The pre-clinical studies support further development of VM1500A long-acting injectable (once per 1-3 months) formulations and Elsulfavirine once weekly oral formulations to enable infrequent dosing for treatment and prevention of HIV-1 infections.
About Viriom
Viriom Inc. is a late-development and commercial-stage biotech company developing, manufacturing and distributing novel and affordable therapies and prophylaxis against life-threatening infections such as HIV and HBV. Viriom holds exclusive worldwide rights from F. Hoffmann-La Roche for VM1500, which it is presently developing as an oral AIDS treatment (Elsulfavirine) for HIV infections, and in the form of innovative long-acting formulations for PrEP and PEP in high-risk patient populations. Viriom is also developing proprietary therapeutics for chronic HBV infections. For more information, please visit www.viriom.com.
Media Contact:
Ronald Demuth
CFO, Viriom
+1(858)-794-4860x321
rdemuth@viriom.com
SOURCE Viriom Inc.